CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02824575
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:43.919967+00:00
- Published At
- 2022-04-04T00:00:00+00:00
- Record Updated At
- 2022-04-04
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Breast Cancer", "Breast Adenocarcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-04-04"- protocolSection.identificationModule.nctId
"NCT02824575"- protocolSection.identificationModule.officialTitle
"Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.